229 results on '"Papa, Sophie"'
Search Results
2. A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
3. Acute kidney injury in patients treated with immune checkpoint inhibitors
4. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products
5. Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
6. Metabolic armouring of CAR and TCR T cells
7. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
8. Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
9. Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
10. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
11. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England
12. A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
13. 362 Allelic variants of MR1 drive cancer and allo-reactivity by MR1-restricted T cells
14. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
15. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
16. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
17. Optimal selection of tumor antigens
18. Problem Solving in Cancer Immunotherapy
19. Conserved allomorphs of MR1 drive specificity of MR1-restricted TCRs
20. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study
21. Provision of cancer care during the COVID-19 pandemic
22. The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports
23. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant
24. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience
25. Papulonodular pigmented lesions in a patient with Stage IV malignant melanoma
26. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
27. Safe delivery of systemic anti‐cancer treatment for skin cancers during the COVID ‐19 pandemic
28. 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
29. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
30. Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort
31. BRAF inhibitors and their immunological effects in malignant melanoma
32. Safe delivery of systemic anti‐cancer treatment for skin cancers during the COVID‐19 pandemic.
33. Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort.
34. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre
35. Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis (Preprint)
36. PMO-47 Clipper (Beclomethasone Dipropionate) as a treatment for checkpoint inhibitor induced enterocolitis
37. 458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
38. ATU-2 A multi-centre study of Infliximab treatment for corticosteroid-refractory Checkpoint Inhibitor Induced enterocolitis
39. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
40. Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
41. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors
42. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells
43. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
44. Abstract LB076: Association between regional COVID-19 hospitalizations and treatment delays amongst confirmed cancer patients in England, UK
45. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
46. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
47. 108 INFLIXIMAB TREATMENT FOR CHECKPOINT INHIBITOR INDUCED COLITIS: CLINICAL OUTCOMES FROM A MULTI-CENTRE STUDY
48. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
49. Abstract P28: COVID-19 infection and mortality in patients with skin malignancies receiving systemic anti-cancer therapy (SACT): The Guy’s Cancer Centre experience
50. Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 death
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.